Slide 1: FDC Limited Investor Presentation Q4FY22 and FY22
FDC LIMITED Investor Presentation Q4FY22 and FY22 www.fdcindia.com 1
Slide 2: Disclaimer
DISCLAIMER This report may contain certain statements that might be considered forward looking. These statements are subject to certain risk and uncertainties, since they are based on certain assumptions and expectations of future events. Actual results may differ materially from those expressed in
Slide 3: Platform to deliver sustainable value
Platform to deliver sustainable value 1 2 3 Best-in-class manufacturing Strong Domestic Business facilities & regulatory Strong Financials ✓ Multiple levers, high growth track record brands to anchor growth ✓ Portfolio of high quality ✓ High Return on Capital ✓ Zifi – Category Creator in manufacturi
Slide 4: Multiple Levers to drive growth
1(a) Multiple Levers to drive growth 3% 3% 5% Anti-Infectives 3% GI Revenue 4% 35% VMN Derma Mix Domestic, 5% Ophthal Export, 14% 86% Cardiac 7% Respiratory Gynaec. 8% Antiviral OTHERS 26% 19.1 Export Sales 50% 20% 25% -0.5 -12% -35% 1535 1527 1819 144 173 259 323 210 MAT 2020/03 MAT 2021/03 MAT 202
Slide 5: Multiple Top Brands to anchor growth
1(a) Multiple Top Brands to anchor growth Brand Molecule Rank Rs. Crs MS % Zifi Cefixime ❶ 301 24.2 Electral Oral Rehydration ❶ 300 72.4 Enerzal Energy Drink ❶ 124 39.1 Vitcofol Folic acid + Cyanocobalamin + Nicotinamide ❽ 79 2.5 Zathrin Azithromycin ❺ 71 4.3 Zifi CV Cefixime + Clavulanic acid ❶ 69
Slide 6: Zifi – Category Leader in CEFIXIME
1(b) Zifi – Category Leader in CEFIXIME Zifi – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Mar 2020 Market Share in MAT Mar 2022 23.7% 24.4% 24.2% 21.7% 22.2% MAT Mar 20 MAT Mar 21 MAT Mar 22 Multiple SKUs to Drivin
Slide 7: Electral – Category Creator & Consistent Leader in Oral Rehydration Salts
1(c) Electral – Category Creator & Consistent Leader in Oral Rehydration Salts Electral –Brand synomous with product category In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Mar 2020 Market Share in MAT Mar 2022 13.6% 13.5% 75.1% 72.4% 72.4% MAT
Slide 8: Enerzal – Category Leader in Energy Drinks
1(d) Enerzal– Category Leader in Energy Drinks Enerzal – Consistent Category Leader In an otherwise fragmented market (Market Share) (Market Shares of Other Players) Market Share in MAT Mar 2020 Market Share in MAT Mar 2022 41.7% 44.0% 39.1% 29.1% 26.5% MAT Mar 20 MAT Mar 21 MAT Mar 22 18.5% 15.0% 1
Slide 9: Manufacturing Facilities & Regulatory Highlights -1
2 (a) Manufacturing Facilities & Regulatory Highlights -1 Location Products Regulatory Approvals ⧫ Sterile ophthalmic preparations ⧫ Ophthalmic facility is MHRA GMP approved, Undergone 7 MHRA inspections between 2003 and Sep 2021. Recent virtual inspection was ⧫ Oral Liquids completed between Sep 6-
Slide 10: Manufacturing Facilities & Regulatory Highlights -2
2 (a) Manufacturing Facilities & Regulatory Highlights -2 Location Products Regulatory Approvals ⧫ Active Pharmaceutical Ingredients ⧫ USFDA approved (APIs) ⧫ WHO ⧫ CEP Roha ⧫ Oral Rehydration Salt ⧫ WHO, Unicef, Tanzania, Ethiopia, Malawi ⧫ Food Plant ⧫ FSSAI, BIS. ⧫ Ready to drink – Energy drink ⧫
Slide 11: Top Countries - Export Sale of APIs & Formulations FY22
2 (b) TOP 10 Countries - Export Sale of APIs & Formulations FY22 Export Formulation Sales – 154Crs Export API Sales - 56Crs 12% 17% 2% 2% Japan USA 25% Germany 3% Ethiopia UK Switzerland 3% New Zealand Taiwan 3% Nepal Saudi Arabia 14% Bangladesh Chile 4% 51% Tanzania 3% South Korea Hong Kong Spain 4
Slide 12: Quarterly Performance
3(a) Quarterly Performance Sales (in Crs) YOY Sales Growth % 445 376 396 332 312 341 337 306 45% 8% 5% 6% 8% 3% -9% -6% Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 EPS in Rs EBITDA % 43% 34% 28% 31% 26% 19% 17% 9% 5.36 5.33 4.18 2.49 5.93 4.36 1.87 0.85 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22
Slide 13: Yearly Performance
3(a) Yearly Performance in crs. (except EPS) FY22 FY21 YoY % Revenue from operations Revenue from operations 1,519 1,325 15% Other income 78.73 97. -19% FY21 1,325 Total Income 1,598 1,423 12% Operating Expenses 1,272 1,001 27% FY22 1,519 EBITDA 326 421 -23% Finance Cost 3 3 -10% EPS Depreciation 37
Slide 14: Financial Summary – 5 Year Scenario
3(b) Financial Summary – 5 Year Scenario Figures in INR Crores FY18 FY19 FY20 FY21 FY22 Total Sales 1,070 1,075 1,323 1,316 1,515 Domestic Sales 926 902 1,064 993 1,304 Domestic business showed good growth of ~30% in FY22 International Sales 144 173 259 323 210 Export business de-growth is of ~35% i
Slide 15: Best in Class Operating Financials
3(c) Best in Class Operating Financials Core ROE % Working Capital Days 39% 36% 68 33% 61 59 60 29% 49 21% Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Book Value Free Cash Flow per share (Rs) 116 14.43 103 91 82 73 8.79 7.92 4.01 2.05 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22 Mar-
Slide 16: For updates and company information, please visit our website
For updates and company information, please visit our website i.e. www.fdcindia.com For specific queries, kindly email on investors@fdcindia.com
Slide 17: Thank you